Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Conditions

• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma

Interventions

• DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
• DRUG: rituximab and lenalidomide
• DRUG: rituximab and bendamustine
• DRUG: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
• DRUG: gemcitabine and oxaliplatin
• BIOLOGICAL: Epcoritamab
• DRUG: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone
• DRUG: Lenalidomide
• DRUG: rituximab, ifosfamide, carboplatin, and etoposide phosphate
• BIOLOGICAL: Epcoritamab
• BIOLOGICAL: Epcoritamab
• BIOLOGICAL: Epcoritamab
• BIOLOGICAL: Epcoritamab
• BIOLOGICAL: Epcoritamab
• BIOLOGICAL: Epcoritamab
• BIOLOGICAL: Epcoritamab
• DRUG: Rituximab and Lenalidomide
• BIOLOGICAL: Epcoritamab

Sponsor

Genmab

Collaborators

• [object Object]